(Q46639249)

23 December 2017

title

Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial (English)

1 reference

23 December 2017

author name string

Mohamed A Aboulghar

1

1 reference

23 December 2017

Ragaa T Mansour

2

1 reference

23 December 2017

Gamal I Serour

3

1 reference

23 December 2017

Hesham G Al-Inany

4

1 reference

23 December 2017

Yehia M Amin

5

1 reference

23 December 2017

M M Aboulghar

6

1 reference

23 December 2017

publication date

1 May 2004

1 reference

23 December 2017

Reproductive BioMedicine Online

published in

1 reference

23 December 2017

volume

8

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

524-527

1 reference

23 December 2017

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Gonadotropin-releasing hormone antagonist: how good is the new hope?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

GnRH antagonist in assisted reproduction: a Cochrane review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Meta-analysis of recombinant versus urinary-derived FSH: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

The use of gonadotropin-releasing hormone antagonist in a flexible protocol: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961098-X

7 January 2021

10.1016/S1472-6483(10)61098-X

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017